<p>根據 MarketBeat 的報道，Adagene Inc. 贊助的 ADR（NASDAQ:ADAG - 獲取免費報告）目前被五家覆蓋該股票的券商給予了 “買入” 的平均推薦。一位分析師對該股票給予了賣出評級，兩位分析師給予了買入評級，另外兩位分析師則對該公司給予了強烈買入評級。在過去一年中，更新了對該股票覆蓋的券商的平均一年目標價為 8.00 美元。</p>
<p>多位股票分析師對 ADAG 股票發表了評論。華爾街 Zen 在 3 月 21 日的報告中將 Adagene 的股票評級上調至 “持有”。Guggenheim 在 4 月 6 日的報告中將 Adagene 的目標價從 9.00 美元提升至 10.00 美元，並給予該股票 “買入” 評級。最後，Weiss Ratings 在 1 月 21 日的報告中重申了對 Adagene 股票的 “賣出（d-）” 評級。</p>
<p><strong>查看我們對 Adagene 的最新分析</strong></p>
<h2>對 Adagene 的對沖基金看法</h2>
<p>大型投資者最近增持或減持了該公司的股份。Fifth Lane Capital LP 在第四季度將其在 Adagene 的持股增加了 427.3%。Fifth Lane Capital LP 現在擁有 145,000 股該公司的股票，價值 274,000 美元，此前在上個季度又收購了 117,500 股。Exome Asset Management LLC 在第四季度收購了價值約 2,004,000 美元的 Adagene 新頭寸。SmartHarvest Portfolios LLC 在第四季度收購了價值約 73,000 美元的 Adagene 新頭寸。Citadel Advisors LLC 在第三季度收購了價值約 80,000 美元的 Adagene 新頭寸。最後，Gordian Capital Singapore Pte Ltd 在第三季度將其在 Adagene 的持股增加了 101.4%。Gordian Capital Singapore Pte Ltd 現在擁有 48,342 股該公司的股票，價值 96,000 美元，此前在上個季度又收購了 24,342 股。目前，9.51% 的股票由機構投資者持有。</p>
<h2>Adagene 價格表現</h2>
<p>NASDAQ:ADAG 週三開盤價為 3.81 美元。Adagene 的 1 年最低價為 1.30 美元，1 年最高價為 4.75 美元。該公司的 50 日移動平均價為 3.48 美元，200 日移動平均價為 2.47 美元。該公司的速動比率為 3.07，流動比率為 3.07，債務與股本比率為 0.03。</p>
<p>Adagene（NASDAQ:ADAG - 獲取免費報告）最近於 2 月 14 日發佈了季度財報。該公司報告季度每股收益為（0.04）美元。該季度的收入為 384 萬美元。研究分析師預計 Adagene 在當前財年將發佈-0.6 的每股收益。</p>
<h2>Adagene 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Adagene Inc.總部位於中國蘇州，是一家臨牀階段的生物製藥公司，專注於抗體基礎治療藥物的發現和開發，主要用於癌症和免疫相關疾病。公司成立於 2017 年，利用其專有的免疫組學技術平台挖掘人類抗體庫，並設計新型單特異性和雙特異性抗體。Adagene 的產品線包括多個處於臨牀前和早期臨牀開發階段的候選藥物，重點針對腫瘤微環境和調節免疫檢查點，以增強抗腫瘤療效。</p>
<p>Adagene 研發工作的核心是其 Bihanc™抗體平台，該平台結合了組合噬菌體展示、基於結構的設計和人工智能，以優化結合親和力、特異性和開發性。</p>
<h2>精選文章</h2>
<ul>
<li>我們更看好的五隻股票，而不是 Adagene</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURBRw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURBRw"/></p>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Adagene 嗎？</h2>
<p>在你考慮 Adagene 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Adagene 並不在名單上。</p>
<p>雖然 Adagene 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

天演藥業

<p>Adagene Inc.（納斯達克代碼：ADAG）獲得了五家券商的平均推薦評級為 “買入”，其中包括一個賣出評級、兩個買入評級和兩個強力買入評級。平均一年目標價為 8.00 美元。最近的機構投資包括 Fifth Lane Capital 將其持股比例提高了 427.3%。Adagene 的股票開盤價為 3.81 美元，過去一年股價範圍為 1.30 美元至 4.75 美元。該公司專注於針對癌症和免疫相關疾病的抗體治療，利用其自主研發的 Bihanc™抗體平台</p>

<p>Shares of Adagene Inc. Sponsored ADR (NASDAQ:ADAG - Get Free Report) have been given an average recommendation of &#34;Buy&#34; by the five brokerages that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, two have given a buy rating and two have issued a strong buy rating on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $8.00.</p>
<div class="lb-trans"><p>根據 MarketBeat 的報道，Adagene Inc. 贊助的 ADR（NASDAQ:ADAG - 獲取免費報告）目前被五家覆蓋該股票的券商給予了 “買入” 的平均推薦。一位分析師對該股票給予了賣出評級，兩位分析師給予了買入評級，另外兩位分析師則對該公司給予了強烈買入評級。在過去一年中，更新了對該股票覆蓋的券商的平均一年目標價為 8.00 美元。</p>
</div><p>A number of equities analysts have commented on ADAG shares. Wall Street Zen upgraded shares of Adagene to a &#34;hold&#34; rating in a report on Saturday, March 21st. Guggenheim boosted their target price on shares of Adagene from $9.00 to $10.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, April 6th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Adagene in a report on Wednesday, January 21st.</p>
<div class="lb-trans"><p>多位股票分析師對 ADAG 股票發表了評論。華爾街 Zen 在 3 月 21 日的報告中將 Adagene 的股票評級上調至 “持有”。Guggenheim 在 4 月 6 日的報告中將 Adagene 的目標價從 9.00 美元提升至 10.00 美元，並給予該股票 “買入” 評級。最後，Weiss Ratings 在 1 月 21 日的報告中重申了對 Adagene 股票的 “賣出（d-）” 評級。</p>
</div><p><strong>Check Out Our Latest Analysis on Adagene</strong></p>
<div class="lb-trans"><p><strong>查看我們對 Adagene 的最新分析</strong></p>
</div><h2>Hedge Funds Weigh In On Adagene</h2>
<div class="lb-trans"><h2>對 Adagene 的對沖基金看法</h2>
</div><p>Large investors have recently added to or reduced their stakes in the company. Fifth Lane Capital LP increased its holdings in shares of Adagene by 427.3% during the fourth quarter. Fifth Lane Capital LP now owns 145,000 shares of the company's stock valued at $274,000 after acquiring an additional 117,500 shares in the last quarter. Exome Asset Management LLC acquired a new position in shares of Adagene during the fourth quarter valued at about $2,004,000. SmartHarvest Portfolios LLC acquired a new position in shares of Adagene during the fourth quarter valued at about $73,000. Citadel Advisors LLC acquired a new position in shares of Adagene during the third quarter valued at about $80,000. Finally, Gordian Capital Singapore Pte Ltd increased its holdings in shares of Adagene by 101.4% during the third quarter. Gordian Capital Singapore Pte Ltd now owns 48,342 shares of the company's stock valued at $96,000 after acquiring an additional 24,342 shares in the last quarter. 9.51% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>大型投資者最近增持或減持了該公司的股份。Fifth Lane Capital LP 在第四季度將其在 Adagene 的持股增加了 427.3%。Fifth Lane Capital LP 現在擁有 145,000 股該公司的股票，價值 274,000 美元，此前在上個季度又收購了 117,500 股。Exome Asset Management LLC 在第四季度收購了價值約 2,004,000 美元的 Adagene 新頭寸。SmartHarvest Portfolios LLC 在第四季度收購了價值約 73,000 美元的 Adagene 新頭寸。Citadel Advisors LLC 在第三季度收購了價值約 80,000 美元的 Adagene 新頭寸。最後，Gordian Capital Singapore Pte Ltd 在第三季度將其在 Adagene 的持股增加了 101.4%。Gordian Capital Singapore Pte Ltd 現在擁有 48,342 股該公司的股票，價值 96,000 美元，此前在上個季度又收購了 24,342 股。目前，9.51% 的股票由機構投資者持有。</p>
</div><h2>Adagene Price Performance</h2>
<div class="lb-trans"><h2>Adagene 價格表現</h2>
</div><p>NASDAQ:ADAG opened at $3.81 on Wednesday. Adagene has a 1-year low of $1.30 and a 1-year high of $4.75. The company has a 50-day moving average of $3.48 and a 200 day moving average of $2.47. The company has a quick ratio of 3.07, a current ratio of 3.07 and a debt-to-equity ratio of 0.03.</p>
<div class="lb-trans"><p>NASDAQ:ADAG 週三開盤價為 3.81 美元。Adagene 的 1 年最低價為 1.30 美元，1 年最高價為 4.75 美元。該公司的 50 日移動平均價為 3.48 美元，200 日移動平均價為 2.47 美元。該公司的速動比率為 3.07，流動比率為 3.07，債務與股本比率為 0.03。</p>
</div><p>Adagene (NASDAQ:ADAG - Get Free Report) last released its quarterly earnings data on Saturday, February 14th. The company reported ($0.04) earnings per share for the quarter. The company had revenue of $3.84 million for the quarter. Research analysts anticipate that Adagene will post -0.6 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Adagene（NASDAQ:ADAG - 獲取免費報告）最近於 2 月 14 日發佈了季度財報。該公司報告季度每股收益為（0.04）美元。該季度的收入為 384 萬美元。研究分析師預計 Adagene 在當前財年將發佈-0.6 的每股收益。</p>
</div><h2>Adagene Company Profile</h2>
<div class="lb-trans"><h2>Adagene 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Adagene Inc, headquartered in Suzhou, China, is a clinical-stage biopharmaceutical company specializing in the discovery and development of antibody-based therapeutics for cancer and immune-related diseases. Founded in 2017, the company leverages its proprietary immunome technology platform to mine human antibody repertoires and engineer novel monospecific and bispecific antibodies. Adagene's pipeline includes multiple candidates in preclinical and early clinical development, with a focus on targeting tumor microenvironments and modulating immune checkpoints to enhance anti-tumor efficacy.</p>
<div class="lb-trans"><p>Adagene Inc.總部位於中國蘇州，是一家臨牀階段的生物製藥公司，專注於抗體基礎治療藥物的發現和開發，主要用於癌症和免疫相關疾病。公司成立於 2017 年，利用其專有的免疫組學技術平台挖掘人類抗體庫，並設計新型單特異性和雙特異性抗體。Adagene 的產品線包括多個處於臨牀前和早期臨牀開發階段的候選藥物，重點針對腫瘤微環境和調節免疫檢查點，以增強抗腫瘤療效。</p>
</div><p>At the core of Adagene's research and development efforts is its Bihanc™ antibody platform, which combines combinatorial phage display, structure-based design and artificial intelligence to optimize binding affinity, specificity and developability.</p>
<div class="lb-trans"><p>Adagene 研發工作的核心是其 Bihanc™抗體平台，該平台結合了組合噬菌體展示、基於結構的設計和人工智能，以優化結合親和力、特異性和開發性。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Adagene</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而不是 Adagene</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QURBRw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ADAG"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。如對本故事有任何問題或意見，請發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Adagene Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Adagene 嗎？</h2>
</div><p>Before you consider Adagene, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Adagene 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adagene wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前立即購買……而 Adagene 並不在名單上。</p>
</div><p>While Adagene currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Adagene 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

天演藥業公司贊助的美國存託憑證（納斯達克代碼：ADAG）被分析師給予 “買入” 的平均推薦